Agios Shares Slump on Sickle Cell Disease Data

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

Agios reports mixed results from sickle cell study, raising doubts about drug's future

The study succeeded on one primary endpoint but failed on another, raising doubts about whether the drug could win approval in sickle cell.

Agios shares fall on mixed sickle cell results for blood disease drug

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention as a rare disease specialist.

Agios reports top line Phase III trial data of mitapivat for sickle cell disease

Agios has announced top line data from the RISE UP Phase III trial assessing mitapivat in subjects aged 16 years or above with sickle cell disease.The post Agios reports top line Phase III trial data of mitapivat for sickle cell disease appeared first on Clinical Trials Arena.

Agios' sickle cell trial falls short as drug doesn't appear to help patient pain crises

Agios Pharmaceuticals’ drug Pyrukynd hit only one of the two primary endpoints in its pivotal trial in sickle cell disease, the company said Wednesday, a significant setback for the company's plans ...